Carol Fosso
Allergy · Indianapolis, INNPI 1356332001
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by GSK at 33.5% of the total. Reporting peaked in 2019 at $1,544 and has fallen 54.3% since, to $706 in 2023.
Across 215 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$301
- Regeneron Healthcare Solutions, Inc.$270
- Amgen$207
- Kaleo, Inc.$205
- plus $993 from 14 others
What the payments were for
- Food & beverage$5,07699%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 70 | $1,721 |
| AstraZeneca | 51 | $1,445 |
| Sanofi | 16 | $301 |
| Regeneron Healthcare Solutions, Inc. | 8 | $270 |
| Amgen | 7 | $207 |
| Kaleo, Inc. | 12 | $205 |
| Novartis | 6 | $200 |
| Genentech USA, Inc. | 5 | $134 |
| Covis Pharma GmbH | 8 | $101 |
| Boehringer Ingelheim | 7 | $100 |
| Pfizer | 5 | $86 |
| Teva Pharmaceuticals USA, Inc. | 5 | $78 |
| Merck | 5 | $72 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Optinose US, Inc. | 4 | $61 |
| Octapharma USA, Inc. | 1 | $29 |
| CSL Behring | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,162 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,330 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,544 |
| Fluticasone Propionate | 15 | $1,807 |
| Montelukast Sodium | 75 | $720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $657 |
| Azelastine Hcl | 11 | $308 |
| Doxepin Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,721 | $27,49237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other allergy in Indianapolis
- Mark HolbreichIndianapolis$2K
- Sanjay PatelHighland$7K
- Lauren RiggValparaiso$4K
- Nagarjuna PonugotiTerre Haute$2K
- Damir MatesicKokomo$2K
- Sai KarlapudiMuncie$1K
- Jay ProchnauLafayette$662
- Naresh PatelFort Wayne$404
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.